
    
      A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics
      and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination with First Line
      Chemotherapy Regimens in Patients with Non-Small Cell Lung Cancer (NSCLC)
    
  